Americans will now buy their weight-loss drugs at Walmart. The same place they bought the food that made them need the drugs. Full circle.
GLP-1 prescriptions are going direct to retail pharmacy chains. Walmart, Costco, and Amazon will fill your Ozempic order right next to the family-size Doritos and the discounted Halloween candy in January. The business model writes itself. Sell someone 47,000 calories of processed garbage on aisle nine, then sell them the injectable peptide on aisle twelve. Vertical integration for the diabetes era.
Costco will move weight-loss drugs in bulk. You wanted one pen? Too bad. Here's a 24-pack. Share them at your book club. Give them out at Christmas. Americans love a deal, especially when that deal requires a forklift.
Amazon will ship it to your door in two hours. Discreet packaging. No judgment. Just you, your doorbell camera, and the knowledge that Jeff Bezos now controls your appetite suppressant supply chain. He already sold you the air fryer you used twice. Might as well let him manage your pancreatic function.
Technical analysts have been saying this for years. The 200-day moving average on American waistlines crossed the 50-day MA in 2019. The breakout was inevitable. Now retail pharmacies will profit from both sides of the trade. They fattened the market. Now they're shorting it. Beautiful, really.
Retail traders will see this headline and buy Walmart calls. They'll tell themselves it's a growth story. A demographic tailwind. An aging population with disposable income and poor impulse control. They'll ignore the fact that Walmart's stock chart looks like an EKG from someone who shops at Walmart.
The real winners here are the people who sold America the sugar, then sold them the drugs, then convinced them it was healthcare.
Photo by on Unsplash
Leave a Comment